Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Shenzhen Kangtai Biological Products Co., Ltd.
  6. News
  7. Summary
    300601   CNE100002Q33

SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.

(300601)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Shenzhen Kangtai Biological Products Co., Ltd. Announces Philippine Food and Drug Administration Approval to BIOKANGTAI COVID-19 Vaccine for Phase III Clinical Trial in the Philippines

08/02/2021 | 03:25am EST

On July 30, Shenzhen Kangtai Biological Products Co., Ltd. was approved by the Philippine Food and Drug Administration to launch the phase III clinical trial of its independently developed Inactivated COVID-19 Vaccine in the local area. Earlier, BIOKANGTAI has already been approved by the Vaccine Expert Panel of the Philippine Department of Science and Technology on June 14, and by the Single Joint Research Ethics Board of the Philippine Department of Health on June 21. BIOKANGTAI is China's leading biopharmaceutical enterprise. Over the past 30 years since its establishment, it has accumulated rich experience in vaccine research and development, and it also has a notable scale of vaccine industrialization in China. In May 2021, BIOKANGTAI's Inactivated COVID-19 Vaccine was approved for emergency use and inoculated on a large-scale within China. In addition, according to the data of phase I/II clinical trials published on the medRxiv platform and in the National Medical Journal of China, in the phase II clinical trial of the vaccine another geometric mean titer of neutralizing antibody against the vaccine virus in the vaccine group on day 0-28 of the immunization program is 2.65 times of that of the serum neutralizing antibody of the convalescents, with an expected protection rate of more than 90%. In June this year, BIOKANGTAI's Inactivated COVID-19 Vaccine first entered Southeast Asia and launched the phase III clinical trial in Malaysia. Meanwhile, BIOKANGTAI is proactively seeking to launch clinical trials in more countries and regions in South America, Europe, etc. It has already obtained clinical approval in Ukraine and is expected to launch trials in early August. The large-scale data will provide a stronger guarantee for vaccine safety and efficacy.


© S&P Capital IQ 2021
All news about SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
11/19Shenzhen Kangtai Biological Products Co., Ltd. Announces Export of Kangtai Adenovirus V..
CI
11/19AstraZeneca's Chinese Distributor Sends First Vaccine Shipment To Indonesia
MT
11/19China's BioKangtai begins first shipment of AstraZeneca's COVID-19 shot
RE
11/03National Agency of Drug and Food Control Grants the Emergency Use Authorization for Cov..
CI
10/21Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Nine Mo..
CI
09/24Shenzhen Kangtai Biological Products Co., Ltd. Announces 2021 Interim Distribution Plan..
CI
09/16Shenzhen Kangtai Biological Products Co., Ltd. Approves Interim Cash Dividend for the F..
CI
09/08Shenzhen Kangtai Biological Products Co., Ltd. Announces Recombinant COVID-19 Vaccine (..
CI
08/30Shenzhen Kangtai Biological Products Co., Ltd. Proposes Cash Dividend for the First Hal..
CI
08/29Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Half Ye..
CI
More news
Financials
Sales 2021 3 818 M 599 M 599 M
Net income 2021 1 165 M 183 M 183 M
Net cash 2021 3 514 M 551 M 551 M
P/E ratio 2021 65,8x
Yield 2021 0,21%
Capitalization 75 924 M 11 907 M 11 908 M
EV / Sales 2021 19,0x
EV / Sales 2022 12,6x
Nbr of Employees 2 043
Free-Float 46,4%
Chart SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Shenzhen Kangtai Biological Products Co., Ltd. Technical Analysis Chart | 300601 | CNE100002Q33 | MarketScreener
Technical analysis trends SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 110,51 CNY
Average target price 177,75 CNY
Spread / Average Target 60,8%
EPS Revisions
Managers and Directors
Wei Min Du Chairman & General Manager
Xiang Miao Chief Financial Officer & Board Secretary
Zhi Yun Lu Chairman-Supervisory Board
Xiang Ming Li Independent Director
Dong Guang Ma Independent Director
Sector and Competitors